enGene Therapeutics Warrants (ENGNW) Financials
Newest figures come from the 10-Q for Q3 FY2026, filed Sep 8, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ENGNW SEC filings page.
This page shows enGene Therapeutics Inc. Warrants (ENGNW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
enGene is funding a rapidly expanding research program while losses and cash outflows deepen and the balance-sheet cushion narrows.
FY2025 changed the financing pattern: research and development rose146.6% from FY2024 while operating cash flow moved from-$48.3M to-$99.2M , yet financing cash flow fell99.4% . That combination indicates heavier internal cash consumption with much less offsetting financing activity, rather than merely a larger reported loss.
The business is increasingly centered on research spending: R&D reached
The balance sheet became less forgiving even though total assets remained
Financial Health Signals
We do not publish a peer-relative financial health score for enGene Therapeutics Inc. Warrants, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
enGene Therapeutics Inc. Warrants passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
enGene Therapeutics Inc. Warrants reported a net loss of $117.3M while operations used $99.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
enGene Therapeutics Inc. Warrants reported an operating loss of $123.2M against $3.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
enGene Therapeutics Inc. Warrants's EBITDA was -$33.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
enGene Therapeutics Inc. Warrants reported a net loss of $32.5M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
enGene Therapeutics Inc. Warrants earned -$0.47 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
enGene Therapeutics Inc. Warrants recorded an outflow of $18.9M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
enGene Therapeutics Inc. Warrants held $41.0M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
enGene Therapeutics Inc. Warrants's quarterly ROE was -14.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.3 percentage points.
Not reported for Q3 2026.
Not reported for Q3 2026.
Not reported for Q3 2026.
Capital Allocation
enGene Therapeutics Inc. Warrants invested $20.1M in research and development in Q3 2026. This represents a decrease of 11.0% from the same quarter a year earlier. Against the prior quarter it is down 9.5%.
enGene Therapeutics Inc. Warrants reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
Not reported for Q3 2026.
ENGNW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $20.1M-11.0% | $22.2M+9.8% | $22.3M+11.4% | $31.7M+181.4% | $22.6M+95.5% | $20.2M+105.1% | $20.0M+254.3% | $11.3M+98.8% |
| SG&A Expenses | $13.9M+88.9% | $9.8M+41.3% | $8.9M+34.5% | $7.8M+25.5% | $7.4M+41.5% | $6.9M-7.2% | $6.6M+29.3% | $6.2M+29.6% |
| Operating Income | -$34.0Mn/m | -$32.0Mn/m | -$31.2Mn/m | -$39.5Mn/m | -$29.9Mn/m | -$27.1Mn/m | -$26.6Mn/m | -$17.5Mn/m |
| EBITDA | -$33.9Mn/m | -$31.8Mn/m | -$31.0Mn/m | N/A | -$29.8Mn/m | -$27.0Mn/m | -$26.5Mn/m | N/A |
| Interest Expense | $843K+11.2% | $745K+1.5% | $732K-2.7% | N/A | $758K+0.9% | $734K+0.8% | $752K+33.6% | N/A |
| Income Tax | $0-100.0% | $0-100.0% | $0-100.0% | -$497K-2715.8% | $239Kn/m | $240K+1042.9% | $18Kn/m | $19K+11.8% |
| Net Income | -$32.5Mn/m | -$30.2Mn/m | -$29.8Mn/m | -$37.9Mn/m | -$29.0Mn/m | -$25.8Mn/m | -$24.6Mn/m | -$15.3Mn/m |
| EPS (Basic) | -$0.47n/m | -$0.43n/m | $0.44-8.3% | $0.73+114.7% | -$0.57-278.1% | -$0.51-234.2% | $0.48 | $0.34 |
| EPS (Diluted) | -$0.47n/m | -$0.43n/m | $0.44-8.3% | $0.73+114.7% | -$0.57-278.1% | -$0.51-234.2% | $0.48 | $0.34 |
| Diluted Shares (Avg) | 70M+36.5% | 70M+36.7% | 67M+31.9% | N/A | 51M+15.7% | 51M+29.3% | 51M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
ENGNW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $288.3M+17.4% | $307.5M+15.3% | $337.1M+17.9% | $221.5M-28.8% | $245.6M-8.0% | $266.7M-2.5% | $285.9M+206.1% | $311.2M+257.8% |
| Current Assets | $277.9M+31.5% | $270.0M+18.4% | $289.2M+30.1% | $201.4M-18.6% | $211.3M-19.6% | $228.0M-15.4% | $222.3M+148.2% | $247.4M+189.5% |
| Cash & Equivalents | $41.0M+25.8% | $29.8M-48.2% | $36.6M-41.3% | $50.2M-71.0% | $32.6M-87.3% | $57.5M-78.3% | $62.3M-27.2% | $173.0M+112.2% |
| Short-Term Investments | $225.3M+33.1% | $228.6M+43.0% | $239.3M+58.0% | $143.6M+119.8% | $169.3Mn/m | $159.8Mn/m | $151.5Mn/m | $65.3Mn/m |
| Long-Term Investments | $0-100.0% | $26.7M-21.7% | $36.6M-37.9% | $8.5M-85.7% | $23.0Mn/m | $34.1Mn/m | $59.0Mn/m | $59.5Mn/m |
| Total Liabilities | $58.0M+29.3% | $52.4M+33.0% | $55.6M+54.4% | $53.8M+39.4% | $44.9M+22.8% | $39.4M+28.8% | $36.0M+15.9% | $38.6M+166.4% |
| Current Liabilities | $27.2M+33.1% | $21.5M+19.4% | $24.6M+90.0% | $32.0M+118.1% | $20.4M+51.9% | $18.0M+185.8% | $13.0M+87.6% | $14.7M+178.9% |
| Non-Current Liabilities | $30.8M+26.1% | $30.9M+44.5% | $31.0M+34.4% | $21.8M-8.9% | $24.4M+5.8% | $21.4M-12.0% | $23.0M-4.6% | $23.9M+159.3% |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m |
| Total Equity | $230.3M+14.8% | $255.2M+12.3% | $281.5M+12.6% | $167.7M-38.5% | $200.7M-12.9% | $227.3M-6.5% | $249.9M+300.7% | $272.6M+276.1% |
| Retained Earnings | -$464.5Mn/m | -$432.0Mn/m | -$401.8Mn/m | -$372.0Mn/m | -$334.2Mn/m | -$305.2Mn/m | -$279.3Mn/m | -$254.7Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
ENGNW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$18.9Mn/m | -$30.5Mn/m | -$28.9Mn/m | -$25.0Mn/m | -$25.6Mn/m | -$22.9Mn/m | -$25.7Mn/m | -$19.6Mn/m |
| Depreciation & Amortization | $100K0.0% | $200K+100.0% | $189K+85.3% | $200K+100.0% | $100K0.0% | $100K0.0% | $102K+27.5% | $100K+35.1% |
| Stock-Based Compensation | $7.8M+202.6% | $4.1M+56.4% | $2.8M+54.9% | N/A | $2.6M+76.8% | $2.6M+38.2% | $1.8M+521.6% | N/A |
| Capital Expenditures | $0-100.0% | $98K+117.8% | $153K-48.8% | $437K+83.6% | $704K+35100.0% | $45K-74.9% | $299K-40.9% | $238K+72.5% |
| Free Cash Flow | -$18.9Mn/m | -$30.6Mn/m | -$29.1Mn/m | -$25.4Mn/m | -$26.3Mn/m | -$23.0Mn/m | -$26.0Mn/m | -$19.8Mn/m |
| Investing Cash Flow | $30.1M+2084.3% | $23.6M+31.7% | -$126.3Mn/m | $40.5Mn/m | $1.4Mn/m | $17.9Mn/m | -$85.0Mn/m | -$125.3Mn/m |
| Financing Cash Flow | $23Kn/m | $74K-62.8% | $141.7M+14165900.0% | $2.0M-96.7% | -$667K-1407.8% | $199K-99.9% | $1K-100.0% | $60.2M+18.3% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ENGNW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -14.1%+0.3pp | -11.8%-0.5pp | -10.6%-0.7pp | -22.6%-17.0pp | -14.4%-8.3pp | -11.4%-5.2pp | -9.8%+7.3pp | -5.6%+108.2pp |
| Return on Assets | -11.3%+0.5pp | -9.8%-0.2pp | -8.8%-0.2pp | -17.1%-12.2pp | -11.8%-6.5pp | -9.7%-4.2pp | -8.6%+2.9pp | -4.9%+90.0pp |
| Current Ratio | 10.21-0.1x | 12.57-0.1x | 11.75-5.4x | 6.30-10.6x | 10.34-9.2x | 12.66-30.1x | 17.16+4.2x | 16.87+0.6x |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.000.0x |
| Liabilities-to-Equity | 0.250.0x | 0.210.0x | 0.20+0.1x | 0.32+0.2x | 0.22+0.1x | 0.170.0x | 0.14-0.4x | 0.14-0.1x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Where enGene Therapeutics Inc. Warrants Ranks
Frequently Asked Questions
No, enGene Therapeutics Inc. Warrants (ENGNW) reported a net loss of $130.4M over the trailing 12 months to July 31, 2026. In fiscal year 2025 it reported a net loss of $117.3M.
enGene Therapeutics Inc. Warrants (ENGNW) had EBITDA of -$122.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
enGene Therapeutics Inc. Warrants (ENGNW) has a return on equity of -69.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
enGene Therapeutics Inc. Warrants (ENGNW) recorded an outflow of $100.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
enGene Therapeutics Inc. Warrants (ENGNW) recorded an outflow of $99.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
enGene Therapeutics Inc. Warrants (ENGNW) had $221.5M in total assets as of fiscal year 2025, including both current and long-term assets.
enGene Therapeutics Inc. Warrants (ENGNW) invested $1.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
enGene Therapeutics Inc. Warrants (ENGNW) invested $94.5M in research and development during fiscal year 2025.
enGene Therapeutics Inc. Warrants (ENGNW) had a current ratio of 6.30 as of fiscal year 2025, which is generally considered healthy.
enGene Therapeutics Inc. Warrants (ENGNW) had a liabilities-to-equity ratio of 0.32 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
enGene Therapeutics Inc. Warrants (ENGNW) had a return on assets of -53.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
At the end of fiscal year 2025, enGene Therapeutics Inc. Warrants (ENGNW) held $202.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $99.2M over that year. Dividing the one by the other, the reported balance equals about 24 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
enGene Therapeutics Inc. Warrants (ENGNW) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
enGene Therapeutics Inc. Warrants (ENGNW) reported a net loss of $117.3M while operations used $99.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
enGene Therapeutics Inc. Warrants (ENGNW) reported an operating loss of $123.2M against $3.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.